Ethical Dilemmas in Pharmacogenomics: Balancing Innovation with Privacy and Equity
Ethical Dilemmas in Pharmacogenomics: Balancing Innovation with Privacy and Equity
FOR IMMEDIATE RELEASE – American Pharmacogenomics Association Issues Statement on Final FDA Rule for Laboratory Developed Tests (LDTs)
The American Pharmacogenomics Association (APGxA) today issued a statement on the Food and Drug Administration’s (FDA) final rule regarding the regulation of laboratory-developed tests (LDTs).
FDA Drops Final Rule On LDTs
Explore the impact of the FDA’s Ruling for LDTs on pharmacogenomics to understand the future of personalized medicine and testing compliance.
Is an FDA Crackdown with 510(k) Clearances for LDTs Inevitable?
Explore the possible intensification of FDA regulations concerning 510(k) clearances for LDTs in the evolving landscape of laboratory testing.
End of content
End of content